Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol
23.4.2023 10:00:00 EEST | Business Wire | Press release
Fresenius Kabi today announced the availability of a single-needle venous access option for the Amicus® Extracorporeal Photopheresis (ECP) System at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
The Amicus Blue System with online ECP was launched in Europe in 2019 with double-needle venous access only. The update announced today includes new software v6.1 for the Amicus Separator, new software v2.1 for the Phelix Photoactivation Device and a new single-use disposable kit that can be configured for single or double-needle venous access. The system also allows clinicians to switch between single and double-needle access at any time during the procedure.
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access. This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs,” said Christian Hauer, President Fresenius Kabi MedTech.
The Amicus ECP System has obtained CE mark for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. The Amicus ECP System is CE marked in compliance with the applicable requirements of the Medical Device Regulation (EU) 2017/745 and includes:
- Amicus Separator
- Phelix Photoactivation Device
- Amicus ECP Apheresis Kits
Amicus Separator is also cleared in Europe and the United States for therapeutic plasma exchange (TPE), red blood cell exchange (RBCx), mononuclear cell (MNC) collection and platelet collection. The Amicus ECP System is not cleared for use in the U.S.
Not all products listed are available or approved for sale in all countries. Contact your local Fresenius Kabi representative for additional information and product availability. Refer to the Amicus Separator Operator’s Manual and Phelix Photoactivation Device Operator’s Manual for a complete list of warnings and precautions associated with the use of these products.
About Extracorporeal Photopheresis
Extracorporeal photopheresis or ECP is a leukapheresis-based therapeutic procedure. The technology is currently approved for the treatment of cutaneous T-cell lymphoma (CTCL). Literature shows that it has also been used for graft versus host disease (GvHD) following bone marrow or stem cell transplant, the rejection of solid organ transplants, and autoimmune diseases where cell-mediated mechanisms are dominant.
An online ECP procedure involves collection of mononuclear cells from the patient, treatment of collected cells with a light sensitive drug, 8-methoxypsoralen and exposure of cells to UV-A light, followed by the reinfusion of treated cells back to the patient. After reinfusion, the treated cells become apoptotic and are believed to be taken up by antigen presenting cells resulting in an immune response. The online ECP process combines cell separation and photoactivation into a single, sterile circuit reducing the risk of infection and cross-contamination.
About Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the most common variants classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Patients may experience itchy, scaly patches or plaques of the skin. As the disease progresses, some patients may experience growth of nodular lesions and large tumors, and internal organ involvement. Treatment is palliative, with the aim to induce long-term remissions and improve patient quality of life.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s global headquarters is in Bad Homburg, Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230423005002/en/
Contact information
Dolores Juarez
+49 152 563 86727
dolores.juarez@fresenius-kabi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AOP Health on Rare Diseases: Information. Collaboration. Innovation.23.2.2026 11:00:00 EET | Press release
Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223167500/en/ Rare Diseases: Collaboration is key. image: AdobeStock_1308212316 “Working in rare diseases sin
ŌURA Named Official Wearable of Team Finland23.2.2026 10:00:00 EET | Press release
ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a long-term partnership as the Official Wearable of Team Finland. As the exclusive provider in the category of continuous health and fitness tracking devices, ŌURA will equip Team Finland Olympic athletes with Oura Ring beginning immediately and continuing through the LA28 Olympic Games and the French Alps 2030 Winter Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223559508/en/ Team Finland delivered a strong showing on the world stage at the Olympic Winter Games Milano Cortina 2026, capturing a total of six Olympic medals across a range of winter sports. During the Games, many Finnish athletes wore Oura Ring to help manage their performance and recovery. The partnership marks the start of a multi-year collaboration focused on supporting athlete preparation, recovery, and overall wellbeing across two Olympic cycles. “At ŌURA, we believe susta
AHS Tower Fully Sold During Development, Generating More Than USD 700 Million23.2.2026 09:55:00 EET | Press release
AHS Properties has confirmed that 100 percent of inventory at AHS Tower has been sold, generating more than USD 700 million in revenue during the development phase, a clear indicator of strong market demand for its flagship commercial project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260222540070/en/ AHS Tower Fully Sold During Development on Sheikh Zayed Road (Photo: AETOSWire) Rising 69 storeys above Sheikh Zayed Road, the tower is positioned within minutes of DIFC and the Museum of the Future. Designed by internationally acclaimed architecture firm Killa Design, with interiors by AHS Atelier, it represents a defining step in AHS Properties’ expansion from ultra-luxury residential developments into Grade A commercial real estate. This demand comes amid a year of exceptional business growth in the UAE, with more than 250,000 new companies established in 2025, bringing the total number of operating companies to 1.4 mil
AGCO Power’s Core80 Engine Named Diesel Engine of the Year 202623.2.2026 09:00:00 EET | Press release
Developed and manufactured in Linnavuori, Finland, the engine represents the most advanced technology in AGCO Power’s new Core engine family. The award is among the most respected in the industry and has been recognizing groundbreaking off‑highway powertrain innovations for 20 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260222724310/en/ Powertrain International Editor-in-Chief Fabio Butturi (left) presents the Diesel Engine of the Year 2026 award to AGCO Power Vice President Juha Tervala. Next to them, AGCO Power Project Manager for Engineering Juha-Pekka Asikainen applauds. In the background: the CORE80 engine. According to Powertrain International Editor‑in‑Chief Fabio Butturi, the decision was straightforward: “Core80 represents exactly the kind of technical courage and innovation we want to highlight. The award truly belongs to the entire Core engine family, which opens a new era for AGCO Power across tractors
SOLUM Brings Retail in Sync to EuroShop 2026 with Integrated Retail Innovations23.2.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) brings ‘Retail in Sync’ to EuroShop 2026, unveiling new retail display innovations and integrated solutions that connect technology, operations and data to create more agile and scalable retail environments. By connecting pricing, communication and store operations within a unified framework, SOLUM aims to help European retailers improve efficiency, create new value and advance sustainability initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260222220569/en/ At EuroShop, SOLUM will present practical applications that combine connected display technologies with data and analytics in real store environments. (Image: SOLUM) At EuroShop, SOLUM will present practical applications that combine connected display technologies with data and analytics in real store environments. Vision AI will demonstrate personalized product recommendations linked to electronic shelf labels (ESL), while Bluetooth Low E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom